Treatment Eligibility

ARE YOUR PATIENTS ELIGIBLE FOR KALYDECO®(ivacaftor)?

Enter your patient's mutations below to see if they are eligible for KALYDECO.

KALYDECO is a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator indicated for the treatment of cystic fibrosis (CF) in patients age 4 months and older who have one mutation in the CFTR gene that is responsive to ivacaftor potentiation based on clinical and/or in vitro assay data.

1.

Please check to see if the mutation was entered correctly.

Please check to see if the mutation was entered correctly.

Learn how to enter 2 or more mutations

 

Please see the responsive mutations below:

Bold = Newly approved mutations. December 2020.

CFTR Mutations Responsive to KALYDECO Based on Clinical and/or In Vitro Data¹⁻³
A1067T G1349D* P67L* S1159P
A120T G178E Q1291R S1251N*
A234D G178R* Q237E S1255P*
A349V G194R Q237H S549N*
A455E* G314E Q359R S549R*
D110E G551D* R1070Q S589N*
D110H G551S* R1070W* S737F
D1152H* G576A R1162L S945L*
D1270N G970D R117C* S977F*
D192G H1375P R117G T1053I
D579G* H939R R117H* T338I
D924N I1027T R117L V1293G
E193K I1139V R117P V232D
E56K I148T R1283M V562I
E822K I175V R170H V754M
E831X* I807M R347H* W1282R
F1052V K1060T R347L Y1014C
F1074L L1480P R352Q* Y1032C
F311del L206W* R553Q 2789+
5G→A*
F311L L320V R668C 3272-
261→G*
F508C L967S R74W 3849+
10kbC→T*
F508C;
S1251N
L997F R75Q 711+3A→G*
G1069R M152V R792G  
G1244E* M952I R933G  
G1249R M952T S1159F  

*Clinical data exist for these mutations.1
Complex/compound mutations where a single allele of the CFTR gene has multiple mutations; these exist independent of the presence of mutations on the other allele.1

Back to top